|Bid||0.4500 x 1800|
|Ask||0.5600 x 3000|
|Day's Range||0.4523 - 0.4680|
|52 Week Range||0.2500 - 1.7800|
|Beta (3Y Monthly)||3.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.00|
GERMANTOWN, Md. , May 16, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the expansion of their ...
- Kenneth C. Carter, PhD appointed Executive Chairman - Strategic initiative to expand pipeline announced GERMANTOWN, Md. , May 14, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical ...
GERMANTOWN, Md., May 6, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, announced that David J. Mazzo, Ph.D. has been appointed to the Company's Board of Directors to be effective June 12, 2019. Dr. Mazzo will replace Stanley Westreich, who is retiring on the effective date. "Dr. Mazzo is a seasoned executive in the biopharma space and brings Neuralstem significant value gained over his 30 years in the pharmaceutical and biotech industries," said Dr. Ken Carter, Executive Chairman of the Board.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! While not a mind-blowing move, it is good to see that the Neuralstem, Inc. (NASDAQ:CUR) share pric...
GERMANTOWN, Md., March 22, 2019 -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem.
Neuralstem Engages Strategic Advisors to Evaluate Dozens of New Technologies GERMANTOWN, Md. , Feb. 7, 2019 /PRNewswire/ -- Neuralstem, Inc. (NASDAQ: CUR), a biopharmaceutical company focused on the development ...
Neuralstem, Inc. (CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, appointed Kenneth C. Carter, Ph.D., as the Company’s Executive Chairman of the Board to be effective on January 1, 2019. Dr. Carter will replace interim CEO, Jim Scully, who will be stepping down. “Dr. Carter brings a wealth of drug development expertise and executive leadership having led both private and public biotechnology companies.
Germantown-based Neuralstem Inc. has been put on notice that its stock could be delisted from the Nasdaq if the company can’t raise its share price above $1 continually within the next six months. The stem cell therapy company said it intends to continue actively monitoring its common stock price and will consider options to boost its value. To return to compliance, Neuralstem stock must close at or above $1 per share for at least 10 consecutive days, though the company could file for an extension or appeal.
Neuralstem Inc (NASDAQ:CUR), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CUR will Read More...
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome - - Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke - -.
If you own shares in Neuralstem Inc (NASDAQ:CUR) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure ofRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 31) Allakos Inc (NASDAQ: ALLK ) (listed July 19 following its IPO) ...